<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004666/" ref="ordinalpos=3768&amp;ncbi_uid=2645631&amp;link_uid=PMC3004666" image-link="/pmc/articles/PMC3004666/figure/f1-cmr-1-079/" class="imagepopup">Figure 1.  From: Evolving role of cetuximab in the treatment of colorectal cancer. </a></div><br /><div class="p4l_captionBody">Simplified EGFR-signaling pathway. Ligands are EGF, TGF-β, ER, and AR. The two main pathways are the PI3K/AKT/mTOR and RAS/RAF/MAPK cascades. The IGF1 receptor can dimerize with EGFR and activate EGFR signaling. Alternatively, downstream crosstalk between signaling cascades may occur. Alterations of downstream effectors known to interfere with EGFR signaling are marked in red.<b>Abbreviations:</b> AR, amphiregulin; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ER, epiregulin; IGF1, insulin-like growth factor-1; TGF-β, transforming growth factor-β.</div></div>